Wuhan Keqian Biology Co Ltd
SSE:688526
Intrinsic Value
Wuhan Keqian Biology Co., Ltd. engages in the research, development, production, and sale of veterinary biological products. [ Read More ]
The intrinsic value of one
Wuhan Keqian Biology Co Ltd
stock under the Base Case scenario is
22.76
CNY.
Compared to the current market price of 19 CNY,
Wuhan Keqian Biology Co Ltd
is
Undervalued by 17%.
Wuhan Keqian Biology Co Ltd's market capitalization is 8.9B CNY.
Wuhan Keqian Biology Co Ltd stock price is 19 CNY.
Wuhan Keqian Biology Co Ltd stock price (19 CNY) is 17% less than its Intrinsic Value (22.76 CNY).
Wuhan Keqian Biology Co Ltd stock price (19 CNY) is 16% less than its DCF Value (22.65 CNY). Open DCF Valuation
Wuhan Keqian Biology Co Ltd stock price (19 CNY) is 17% less than its Relative Value (22.87 CNY). Open Relative Valuation
Wuhan Keqian Biology Co Ltd has upside potential of 43% compared to the average analyst price target.
Open Wall St Estimates
Wuhan Keqian Biology Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
Wuhan Keqian Biology Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 14%.
Wuhan Keqian Biology Co Ltd's Revenue has grown by 13% over the past 12 months.
Wuhan Keqian Biology Co Ltd's Revenue is forecast to grow at a rate of 14% per year over the next 3 years.
Wuhan Keqian Biology Co Ltd has positive three-year average ROE (Return on Equity): 18%. The company is efficient at transforming stockholders' equity into net income.
Wuhan Keqian Biology Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 31% to 14%.
Wuhan Keqian Biology Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 53% to 14%.
Wuhan Keqian Biology Co Ltd has positive Operating Income for the last twelve months.
Wuhan Keqian Biology Co Ltd has positive Net Income for the last twelve months.
Wuhan Keqian Biology Co Ltd has very high three-year average ROIC (Return on Invested Capital): 28%. The company is very efficient at using invested capital to generate operating income.
Wuhan Keqian Biology Co Ltd has positive Gross Profit for the last twelve months.
Wuhan Keqian Biology Co Ltd has positive Free Cash Flow for the last twelve months.
Wuhan Keqian Biology Co Ltd's short-term assets (3B CNY) exceed its short-term liabilties (846m CNY).
Wuhan Keqian Biology Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.07.
Wuhan Keqian Biology Co Ltd's long-term assets (5B CNY) exceed its long-term liabilties (972m CNY).
Wuhan Keqian Biology Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (275m CNY).
Wuhan Keqian Biology Co Ltd's Altman Z-Score is very high and is equal to 7.37.
Valuation Backtest
Wuhan Keqian Biology Co Ltd
Run backtest to discover the historical profit from buying and selling
Wuhan Keqian Biology Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Wuhan Keqian Biology Co Ltd
Balance Sheet Decomposition
Wuhan Keqian Biology Co Ltd
| Current Assets | 3B |
| Cash & Short-Term Investments | 1.6B |
| Receivables | 399.2m |
| Other Current Assets | 972m |
| Non-Current Assets | 1.8B |
| Long-Term Investments | 200k |
| PP&E | 855.3m |
| Intangibles | 62.2m |
| Other Non-Current Assets | 846.6m |
| Current Liabilities | 845.7m |
| Accounts Payable | 139.8m |
| Accrued Liabilities | 43.9m |
| Short-Term Debt | 268.4m |
| Other Current Liabilities | 393.6m |
| Non-Current Liabilities | 126.2m |
| Long-Term Debt | 6.4m |
| Other Non-Current Liabilities | 119.8m |
Earnings Waterfall
Wuhan Keqian Biology Co Ltd
|
Revenue
|
1.1B
CNY
|
|
Cost of Revenue
|
-302.2m
CNY
|
|
Gross Profit
|
840m
CNY
|
|
Operating Expenses
|
-360.4m
CNY
|
|
Operating Income
|
479.6m
CNY
|
|
Other Expenses
|
3.9m
CNY
|
|
Net Income
|
483.5m
CNY
|
Free Cash Flow Analysis
Wuhan Keqian Biology Co Ltd
Profitability Score
Profitability Due Diligence
Wuhan Keqian Biology Co Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Wuhan Keqian Biology Co Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Wuhan Keqian Biology Co Ltd's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Score
Wuhan Keqian Biology Co Ltd's solvency score is 86/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Wuhan Keqian Biology Co Ltd
According to Wall Street analysts, the average 1-year price target for
Wuhan Keqian Biology Co Ltd
is 27.24 CNY
with a low forecast of 24.24 CNY and a high forecast of 29.54 CNY.
Shareholder Return
Price
Wuhan Keqian Biology Co Ltd
| Average Annual Return | -4.6% |
| Standard Deviation of Annual Returns | 40% |
| Max Drawdown | -71% |
| Market Capitalization | 8.9B CNY |
| Shares Outstanding | 466 168 016 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Wuhan Keqian Biology Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Wuhan Keqian Biology Co., Ltd. engages in the research, development, production, and sale of veterinary biological products. The company is headquartered in Wuhan, Hubei and currently employs 848 full-time employees. The company went IPO on 2020-09-22. The firm's main products are vaccines for swine and poultry. The firm mainly conducts its businesses within the China market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Wuhan Keqian Biology Co Ltd
stock under the Base Case scenario is
22.76
CNY.
Compared to the current market price of 19 CNY,
Wuhan Keqian Biology Co Ltd
is
Undervalued by 17%.
You don't have any saved screeners yet
